SCHEMBL1787567

SCHEMBL1787567

COc1ccc(CNC(=O)c2ccc3c(c2)CCN(C2=CC=C2)CC3)c(OC)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.53
LMNA P02545 4/20 0.51
MAPT P10636 3/20 0.49
TP53 P04637 3/20 0.49
ROCK2 O75116 1/20 0.47
DRD2 P14416 2/20 0.47
DRD4 P21917 2/20 0.47
DRD3 P35462 2/20 0.47
TMEM97 Q5BJF2 2/20 0.47
ALDH1A1 P00352 1/20 0.46
TSHR P16473 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
PPARG P37231 1/20 0.46
GAA P10253 1/20 0.45
HPGD P15428 1/20 0.45
EPHX2 P34913 1/20 0.44
MMP2 P08253 1/20 0.44
MMP13 P45452 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1787455 0.86 MAPT (0.55) NAMPTLMNAMAPTTP53TSHR
SCHEMBL1787565 0.81 HRH3 (0.54) NAMPTLMNAMAPTTP53ROCK2
SCHEMBL1786904 0.79 MAPT (0.44) LMNAMAPTTP53ROCK2NPC1
SCHEMBL1788120 0.79 HDAC6 (0.37) MAPTTP53DRD2DRD3ALDH1A1
SCHEMBL1787706 0.78 HDAC6 (0.43) NAMPTTP53NPC1RAB9A
SCHEMBL1787618 0.78 ROCK2 (0.46) MAPTTP53ROCK2DRD2DRD4
SCHEMBL1790098 0.77 MAPT (0.48) LMNAMAPTTP53DRD2DRD4
SCHEMBL1790327 0.77 GAA (0.48) LMNAMAPTTP53ROCK2ALDH1A1
SCHEMBL1789725 0.77 EPHX2 (0.48) LMNAMAPTTP53ALDH1A1HPGD
SCHEMBL1788808 0.77 RAB9A (0.48) NAMPTLMNAMAPTTP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2326625-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS Takeda Pharmaceutical Company Limited (JP) 2011-06-01 EP disclosed
US-20110124626-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-26 US disclosed
WO-2010007382-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124626-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS HRH4, HRH3, HRH2 NAMPT 4540/4885LMNA 2172/4885MAPT 3598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.